Meeting
Plenary Presentations
Abstract Number: Plenary
SHM Converge 2021
Background: Antibiotics targeted against C. difficile bacteria are necessary, but insufficient, to achieve a durable clinical response because they have no effect on C. difficile spores that germinate within a disrupted microbiome. ECOSPOR-III evaluated SER-109, an investigational, biologically-derived microbiome therapeutic of purified Firmicute spores for treatment of recurrent CDI. Methods: Adults ≥18 years with recurrent […]
Abstract Number: 125
SHM Converge 2023
Background: Antibiotics used to treat Clostridioides difficile infection (CDI) can predispose patients to recurrent CDI (rCDI). Gut microbiome restoration by fecal microbiota transplantation is recommended by multiple guidelines after ≥2 episodes of rCDI, with no guideline-recommended options to restore the microbiome earlier in the course of CDI. RBX2660 is a standardized, microbiota-based live biotherapeutic being […]
Abstract Number: 127
SHM Converge 2023
Background: Clostridioides difficile is an opportunistic pathogen that causes an estimated 500,000 infections per year in the United States. RBX2660, a standardized, microbiota-based live biotherapeutic, is being investigated as a treatment option for recurrent C. difficile infection (rCDI). RBX2660 has demonstrated consistent tolerability and efficacy in reducing rCDI across 6 clinical studies. We present a […]
Abstract Number: L10
SHM Converge 2022
Background: Clostridioides difficile infection (CDI) is a leading healthcare-associated infection causing debilitating diarrhea, life-threatening complications, 20,500 deaths and healthcare costs of up to $5.4 billion annually in the US. The main driver of CDI costs is hospitalizations, and patients with higher CDI recurrence rates have more hospitalizations and emergency department visits and longer hospital stays. […]
Plenary Presentations
Abstract Number: Plenary
SHM Converge 2021
Background: Antibiotics targeted against C. difficile bacteria are necessary, but insufficient, to achieve a durable clinical response because they have no effect on C. difficile spores that germinate within a disrupted microbiome. ECOSPOR-III evaluated SER-109, an investigational, biologically-derived microbiome therapeutic of purified Firmicute spores for treatment of recurrent CDI. Methods: Adults ≥18 years with recurrent […]